DMXL1

Summary

DMXL1 (Dmx like 1, HGNC:2937) is a protein-coding gene on chromosome 5q23.1, encoding DmX-like protein 1 (Q9Y485).

The protein encoded by this gene is a member of the WD repeat superfamily of proteins, which have regulatory functions. This gene is expressed in many tissue types including several types of eye tissue, and it has been associated with ocular phenotypes. In addition, it is upregulated in cultured cells that overexpress growth factor independence 1B, a transcription factor that is essential for hematopoietic cell development. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 1657 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 590 total
• MANE Select transcript: NM_001290321

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2937
Approved symbol	DMXL1
Name	Dmx like 1
Location	5q23.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000172869
Ensembl biotype	protein_coding
OMIM	605671
Entrez	1657

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding_CDS_not_defined, 4 protein_coding, 3 retained_intron

ENST00000311085, ENST00000502516, ENST00000503802, ENST00000504031, ENST00000504497, ENST00000505312, ENST00000507552, ENST00000509902, ENST00000510924, ENST00000511622, ENST00000512281, ENST00000514151, ENST00000514595, ENST00000515335, ENST00000539542, ENST00000939842

RefSeq mRNA: 8 — MANE Select: NM_001290321 NM_001290321, NM_001349239, NM_001349240, NM_001387933, NM_001387934, NM_001387937, NM_001387938, NM_005509

CCDS: CCDS4125, CCDS75289

Canonical transcript exons

ENST00000539542 — 44 exons

Exon	Start	End
ENSE00001083130	119197755	119197956
ENSE00001202207	119133494	119134178
ENSE00001202211	119133132	119133385
ENSE00001272322	119196371	119196456
ENSE00001272476	119129211	119129423
ENSE00001272492	119118815	119119004
ENSE00001272517	119105180	119105258
ENSE00001272572	119246995	119249127
ENSE00001367752	119147249	119147470
ENSE00001368091	119134268	119134389
ENSE00001377433	119148739	119150421
ENSE00001400702	119167603	119167864
ENSE00001404246	119166616	119166781
ENSE00001404744	119193828	119193970
ENSE00001409422	119189708	119189886
ENSE00001412462	119177996	119178244
ENSE00001417452	119177357	119177484
ENSE00001417604	119165183	119165280
ENSE00001423096	119164507	119164676
ENSE00001425422	119175261	119175337
ENSE00001426459	119151929	119152036
ENSE00001429600	119171778	119171969
ENSE00001434520	119170190	119171280
ENSE00002224323	119206834	119206896
ENSE00002279392	119071087	119071656
ENSE00003489787	119101935	119102006
ENSE00003489981	119240419	119240471
ENSE00003493530	119220940	119221081
ENSE00003495869	119238989	119239080
ENSE00003506049	119220472	119220593
ENSE00003509345	119224709	119224769
ENSE00003511570	119146837	119146956
ENSE00003572488	119097979	119098104
ENSE00003573913	119244359	119244576
ENSE00003602143	119114475	119114541
ENSE00003608671	119143841	119143930
ENSE00003616513	119144536	119144638
ENSE00003619105	119120971	119121139
ENSE00003641587	119116158	119116336
ENSE00003642078	119203319	119203436
ENSE00003648795	119233340	119233467
ENSE00003662943	119237322	119237414
ENSE00003684570	119216901	119216987
ENSE00003687950	119110151	119110283

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 96.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.9455 / max 685.2201, expressed in 1814 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
58107	9.5846	1708
58108	9.2302	1735
58106	3.3798	1348
58105	0.7509	467

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
choroid plexus epithelium	UBERON:0003911	96.92	gold quality
pigmented layer of retina	UBERON:0001782	96.85	gold quality
retina	UBERON:0000966	96.83	gold quality
endothelial cell	CL:0000115	96.18	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.88	gold quality
calcaneal tendon	UBERON:0003701	95.67	gold quality
nephron tubule	UBERON:0001231	94.61	gold quality
epithelium of nasopharynx	UBERON:0001951	94.38	gold quality
secondary oocyte	CL:0000655	94.27	gold quality
corpus callosum	UBERON:0002336	94.23	gold quality
oocyte	CL:0000023	93.91	gold quality
parietal pleura	UBERON:0002400	93.55	gold quality
visceral pleura	UBERON:0002401	93.37	gold quality
sural nerve	UBERON:0015488	92.95	gold quality
blood vessel layer	UBERON:0004797	92.92	gold quality
adrenal tissue	UBERON:0018303	92.87	gold quality
germinal epithelium of ovary	UBERON:0001304	92.85	gold quality
pleura	UBERON:0000977	92.83	gold quality
superficial temporal artery	UBERON:0001614	92.74	gold quality
tibia	UBERON:0000979	92.63	gold quality
oral cavity	UBERON:0000167	92.26	gold quality
tonsil	UBERON:0002372	92.15	gold quality
mucosa of paranasal sinus	UBERON:0005030	92.14	gold quality
jejunal mucosa	UBERON:0000399	92.13	gold quality
pons	UBERON:0000988	92.05	gold quality
gingival epithelium	UBERON:0001949	91.98	gold quality
skin of hip	UBERON:0001554	91.92	gold quality
subthalamic nucleus	UBERON:0001906	91.77	gold quality
upper leg skin	UBERON:0004262	91.67	gold quality
inferior olivary complex	UBERON:0002127	91.62	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

163 targeting DMXL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-5696	99.98	72.36	4487

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
		ENSDARG00000098599
mus_musculus	Dmxl1	ENSMUSG00000037416
rattus_norvegicus	Dmxl1	ENSRNOG00000024671
drosophila_melanogaster	Rbcn-3A	FBGN0023458
caenorhabditis_elegans		WBGENE00004313

Paralogs (1): DMXL2 (ENSG00000104093)

Protein

Protein identifiers

DmX-like protein 1 — Q9Y485 (reviewed: Q9Y485)

All UniProt accessions (3): E7EMZ0, Q9Y485, F5H269

UniProt curated annotations — full annotation on UniProt →

Tissue specificity. Expressed in bone, breast, eye, foreskin, heart, parathyroid, small intestine, testis, tonsils, placenta and uterus.

RefSeq proteins (8): NP_001277250, NP_001336168, NP_001336169, NP_001374862, NP_001374863, NP_001374866, NP_001374867, NP_005500 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR022033	Rav1p_C	Domain
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR052208	DmX-like/RAVE_component	Family

Pfam: PF00400, PF12234

UniProt features (41 total): repeat 16, modified residue 11, region of interest 4, sequence variant 4, sequence conflict 3, compositionally biased region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for Q9Y485 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 324, 422, 425, 436, 574, 918, 924, 1830, 1896, 1908, 1970

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 217 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, GCANCTGNY_MYOD_Q6, AREB6_03, BROWNE_HCMV_INFECTION_48HR_DN, TCF4_Q5, ONKEN_UVEAL_MELANOMA_UP, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, GOBP_VACUOLAR_ACIDIFICATION, MYOD_Q6, SCHLOSSER_SERUM_RESPONSE_DN, GOBP_REGULATION_OF_PH, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, GOBP_MONOATOMIC_ION_HOMEOSTASIS, FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN, BASAKI_YBX1_TARGETS_DN

GO Biological Process (1): vacuolar acidification (GO:0007035)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): RAVE complex (GO:0043291)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular pH reduction	1
binding	1
cytoplasm	1
protein-containing complex	1

Protein interactions and networks

STRING

1504 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DMXL1	RAB3GAP1	Q15042	682
DMXL1	RAB3GAP2	Q9H2M9	649
DMXL1	MADD	Q8WXG6	606
DMXL1	WDR7	Q9Y4E6	545
DMXL1	RPS6KA3	P51812	522
DMXL1	SNX27	Q96L92	509
DMXL1	TTLL2	Q9BWV7	506
DMXL1	ROGDI	Q9GZN7	462
DMXL1	COX7B2	Q8TF08	460
DMXL1	ATP6V1A	P38606	453
DMXL1	GPR153	Q6NV75	443
DMXL1	RAB3A	P20336	441
DMXL1	PLEKHG1	Q9ULL1	435
DMXL1	ADPGK	Q9BRR6	428
DMXL1	MSANTD2	Q6P1R3	419

IntAct

37 interactions, top by confidence:

A	B	Type	Score
ATP6V1C2	ATP6V1G1	psi-mi:“MI:0914”(association)	0.640
STK4	STRN	psi-mi:“MI:0914”(association)	0.610
ATP6V1B2	ATP6V1G1	psi-mi:“MI:0914”(association)	0.530
RPN1	APBB1	psi-mi:“MI:0914”(association)	0.530
ZNRD2	MYO9A	psi-mi:“MI:0914”(association)	0.530
ATP6V1G2	ATP6V1B1	psi-mi:“MI:0914”(association)	0.530
DMXL1	PDIA6	psi-mi:“MI:0915”(physical association)	0.400
DMXL1	H2AC14	psi-mi:“MI:0915”(physical association)	0.400
RNASEH2A	PHF20L1	psi-mi:“MI:0914”(association)	0.350
RAP1B	KLC1	psi-mi:“MI:0914”(association)	0.350
ATP6V1C2	POTEF	psi-mi:“MI:0914”(association)	0.350
ROGDI		psi-mi:“MI:0914”(association)	0.350
ATP6V1B1	ATP6V1G1	psi-mi:“MI:0914”(association)	0.350
RYBP	PIPSL	psi-mi:“MI:0914”(association)	0.350
RYBP	FAM186A	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
ATP6V1E1	ATP6V1D	psi-mi:“MI:0914”(association)	0.350
ATP6V1F	MID1	psi-mi:“MI:0914”(association)	0.350
ATP6V1G1	MRPL3	psi-mi:“MI:0914”(association)	0.350
ATP6V1H	ATP6V1G1	psi-mi:“MI:0914”(association)	0.350
DDOST	ATL3	psi-mi:“MI:0914”(association)	0.350
OST4	ATL3	psi-mi:“MI:0914”(association)	0.350
RPN2	APBB1	psi-mi:“MI:0914”(association)	0.350
STT3B	APBB1	psi-mi:“MI:0914”(association)	0.350
DMXL1	LLGL1	psi-mi:“MI:0914”(association)	0.350
WDR7	DMXL2	psi-mi:“MI:0914”(association)	0.350
atp6v1c_human	POTEF	psi-mi:“MI:0914”(association)	0.350
atp6v1g_human	HSPA8	psi-mi:“MI:0914”(association)	0.350
PPP4R1L	IFT56	psi-mi:“MI:0914”(association)	0.350

BioGRID (78): DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-MS), DMXL1 (Affinity Capture-RNA), DMXL1 (Proximity Label-MS), DMXL1 (Proximity Label-MS), DMXL1 (Affinity Capture-RNA), DMXL1 (Two-hybrid), DMXL1 (Proximity Label-MS)

ESM2 similar proteins: A1L3L1, A2RT67, A3KPW7, A4IIA7, A8C750, A8C752, D2HNY3, E1BGQ2, E1C3P4, Q08CL8, Q08DZ8, Q0IHB3, Q149N8, Q1RMU2, Q1RMZ1, Q3MJ13, Q3T1H6, Q5F3F2, Q5RED8, Q5VVJ2, Q5ZJ87, Q66J91, Q69Z66, Q6AYF5, Q6DE97, Q6GR37, Q6P1E7, Q6PNC0, Q6YHU6, Q7TPQ3, Q8BKW4, Q8BXK4, Q8IWR0, Q8IYF3, Q8IZE3, Q8K2I9, Q8NA31, Q8NEN0, Q8NFZ0, Q96EW2

Diamond homologs: P87314, Q6PNC0, Q8BPN8, Q8TDJ6, Q9Y485

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DMXL1	“form complex”	“RAVE complex, DMXL1 variant”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 52 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy	6	106.1×	5e-10
Insulin receptor recycling	9	90.2×	5e-14
Transferrin endocytosis and recycling	9	87.2×	5e-14
ROS and RNS production in phagocytes	9	79.5×	8e-14
PD-L1(CD274) glycosylation and translocation to plasma membrane	5	68.3×	3e-07
Amino acids regulate mTORC1	9	47.5×	1e-11
Maturation of spike protein	5	34.9×	9e-06
Maturation of DENV proteins	5	27.8×	3e-05

GO biological processes:

GO term	Partners	Fold	FDR
synaptic vesicle lumen acidification	7	145.6×	5e-12
vacuolar acidification	6	97.7×	2e-09
regulation of macroautophagy	8	52.6×	2e-10
proton transmembrane transport	6	41.6×	4e-07
protein N-linked glycosylation	5	29.3×	3e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

590 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	437
Likely benign	39
Benign	54

Top pathogenic / likely-pathogenic (0)

SpliceAI

7158 predictions. Top by Δscore:

Variant	Effect	Δscore
5:119071653:CACGG:C	donor_loss	1.0000
5:119071656:GGT:G	donor_loss	1.0000
5:119071657:G:GC	donor_loss	1.0000
5:119071657:G:GG	donor_gain	1.0000
5:119071658:T:A	donor_loss	1.0000
5:119071659:GAGT:G	donor_loss	1.0000
5:119097973:TTTTA:T	acceptor_loss	1.0000
5:119097974:TTTAG:T	acceptor_loss	1.0000
5:119097975:TTAG:T	acceptor_loss	1.0000
5:119097976:TAGG:T	acceptor_loss	1.0000
5:119097977:A:AG	acceptor_gain	1.0000
5:119097977:AG:A	acceptor_gain	1.0000
5:119097978:G:GG	acceptor_gain	1.0000
5:119097978:GG:G	acceptor_gain	1.0000
5:119097978:GGCTT:G	acceptor_gain	1.0000
5:119098101:CAAG:C	donor_loss	1.0000
5:119098102:AAGGT:A	donor_loss	1.0000
5:119110284:G:GG	donor_gain	1.0000
5:119114470:TACA:T	acceptor_loss	1.0000
5:119114471:ACAGA:A	acceptor_loss	1.0000
5:119114472:CAG:C	acceptor_loss	1.0000
5:119114473:A:AG	acceptor_gain	1.0000
5:119114473:A:AT	acceptor_loss	1.0000
5:119114474:G:GG	acceptor_gain	1.0000
5:119114474:GA:G	acceptor_gain	1.0000
5:119114474:GAACT:G	acceptor_gain	1.0000
5:119116153:CTTA:C	acceptor_loss	1.0000
5:119116154:TTA:T	acceptor_loss	1.0000
5:119116155:TAG:T	acceptor_loss	1.0000
5:119116156:A:AG	acceptor_gain	1.0000

AlphaMissense

20100 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:119116308:T:A	W239R	1.000
5:119116308:T:C	W239R	1.000
5:119118870:T:A	W267R	1.000
5:119118870:T:C	W267R	1.000
5:119129288:T:A	W394R	1.000
5:119129288:T:C	W394R	1.000
5:119133332:T:A	W506R	1.000
5:119133332:T:C	W506R	1.000
5:119133747:T:C	L608P	1.000
5:119133755:T:A	W611R	1.000
5:119133755:T:C	W611R	1.000
5:119133836:T:C	F638L	1.000
5:119133837:T:C	F638S	1.000
5:119133838:T:A	F638L	1.000
5:119133838:T:G	F638L	1.000
5:119134038:T:C	L705P	1.000
5:119134046:T:A	W708R	1.000
5:119134046:T:C	W708R	1.000
5:119177478:T:A	W2294R	1.000
5:119177478:T:C	W2294R	1.000
5:119216970:G:C	A2645P	1.000
5:119233343:T:C	L2760P	1.000
5:119233367:T:A	V2768D	1.000
5:119233381:T:A	W2773R	1.000
5:119233381:T:C	W2773R	1.000
5:119071589:T:C	L7P	0.999
5:119071605:C:A	N12K	0.999
5:119071605:C:G	N12K	0.999
5:119097980:C:A	A30D	0.999
5:119098010:T:C	L40P	0.999

dbSNP variants (sampled 300 via entrez): RS1000006788 (5:119082854 C>A,G), RS1000016499 (5:119190375 C>T), RS1000028711 (5:119225666 A>G), RS1000035757 (5:119235164 A>G), RS1000042801 (5:119170552 G>T), RS1000061990 (5:119198017 C>T), RS1000066002 (5:119116528 C>T), RS1000074682 (5:119185071 T>A,C), RS1000087663 (5:119147642 C>G,T), RS1000089122 (5:119074006 C>T), RS1000110621 (5:119083317 G>C), RS1000113691 (5:119139247 A>C,T), RS1000122198 (5:119213729 C>G,T), RS1000130611 (5:119159384 G>A), RS1000145945 (5:119108858 A>G)

Disease associations

OMIM: gene MIM:605671 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001915_11	Alzheimer’s disease (cognitive decline)	9.000000e-07
GCST005956_40	Waist-to-hip ratio adjusted for BMI	2.000000e-06
GCST005958_18	Waist-to-hip ratio adjusted for BMI (age >50)	9.000000e-07
GCST005962_27	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	9.000000e-09
GCST009391_1634	Metabolite levels	1.000000e-06
GCST009798_70	Asthma	3.000000e-11
GCST011068_1	Cognitive impairment in depression	5.000000e-06
GCST90002390_139	Mean corpuscular hemoglobin	4.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0007787	plasma betaine measurement
EFO:0004527	mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	decreases expression	2
Quercetin	decreases expression, affects expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression, increases expression	1
kojic acid	decreases expression	1
trichostatin A	affects expression	1
beta-lapachone	decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	increases methylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
3-deazaneplanocin	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
oxamflatin	increases expression	1
apicidin	increases expression	1
acyline	increases expression	1
scriptaid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
suberoyl bis-hydroxamic acid	increases expression	1
jinfukang	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Arsenic Trioxide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.